Rock Springs Capital Management L.P. 13F annual report
Rock Springs Capital Management L.P. is an investment fund managing more than $3.31 trillion ran by Nnamdi Etoh. There are currently 106 companies in Etoh’s portfolio. The largest investments include Blueprint Medicines Corp and Unitedhealth Inc, together worth $405 billion.
$3.31 trillion Assets Under Management (AUM)
As of 7th August 2024, Rock Springs Capital Management L.P.’s top holding is 2,460,417 shares of Blueprint Medicines Corp currently worth over $265 billion and making up 8.0% of the portfolio value.
Relative to the number of outstanding shares of Blueprint Medicines Corp, Rock Springs Capital Management L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 275,000 shares of Unitedhealth Inc worth $140 billion, whose value grew 11.1% in the past six months.
The third-largest holding is Intuitive Surgical Inc worth $133 billion and the next is Neurocrine Biosciences worth $129 billion, with 940,000 shares owned.
Currently, Rock Springs Capital Management L.P.'s portfolio is worth at least $3.31 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Rock Springs Capital Management L.P.
The Rock Springs Capital Management L.P. office and employees reside in Baltimore, Maryland. According to the last 13-F report filed with the SEC, Nnamdi Etoh serves as the Chief Financial Officer at Rock Springs Capital Management L.P..
Recent trades
In the most recent 13F filing, Rock Springs Capital Management L.P. revealed that it had opened a new position in
Insmed Inc and bought 808,356 shares worth $54.2 billion.
This means they effectively own approximately 0.1% of the company.
Insmed Inc makes up
2.3%
of the fund's Health Care sector allocation and has grown its share price by 242.5% in the past year.
The investment fund also strengthened its position in Unitedhealth Inc by buying
45,000 additional shares.
This makes their stake in Unitedhealth Inc total 275,000 shares worth $140 billion.
Unitedhealth Inc soared 12.4% in the past year.
On the other hand, there are companies that Rock Springs Capital Management L.P. is getting rid of from its portfolio.
Rock Springs Capital Management L.P. closed its position in Shockwave Med Inc on 14th August 2024.
It sold the previously owned 135,000 shares for $44 billion.
Nnamdi Etoh also disclosed a decreased stake in Blueprint Medicines Corp by approximately 0.1%.
This leaves the value of the investment at $265 billion and 2,460,417 shares.
One of the largest hedge funds
The two most similar investment funds to Rock Springs Capital Management L.P. are Acr Alpine Capital Research and Massmutual Trust Co Fsb/adv. They manage $3.3 trillion and $3.3 trillion respectively.
Nnamdi Etoh investment strategy
Rock Springs Capital Management L.P.’s portfolio is diversified across 4 sectors.
Currently, their heaviest sector is Health Care — making up 72.4% of
the total portfolio value.
The fund focuses on investments in the United States as
57.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
12% of the total holdings value.
On the other hand, small-cap stocks make up only 7.5% of the portfolio.
The average market cap of the portfolio companies is close to $20.7 billion.
The complete list of Rock Springs Capital Management L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Blueprint Medicines Corp |
1.52%
2,460,417
|
$265,183,744,000 | 8.02% |
| Unitedhealth Group Inc |
19.57%
275,000
|
$140,046,500,000 | 4.24% |
| Intuitive Surgical Inc |
No change
298,500
|
$132,787,725,000 | 4.02% |
| Neurocrine Biosciences, Inc. |
10.89%
940,000
|
$129,409,800,000 | 3.91% |
| Eli Lilly & Co |
17.68%
121,500
|
$110,003,670,000 | 3.33% |
| Argenx Se |
No change
229,250
|
$98,586,670,000 | 2.98% |
| Acadia Healthcare Company In |
No change
1,177,500
|
$79,528,350,000 | 2.41% |
| Ultragenyx Pharmaceutical In |
8.40%
1,924,072
|
$79,079,359,000 | 2.39% |
| Evolent Health Inc |
2.26%
4,077,500
|
$77,961,800,000 | 2.36% |
| Madrigal Pharmaceuticals Inc |
14.14%
245,499
|
$68,779,000,000 | 2.08% |
| Boston Scientific Corp. |
33.67%
817,500
|
$62,955,675,000 | 1.90% |
| Freshpet Inc |
27.55%
480,000
|
$62,107,200,000 | 1.88% |
| Alnylam Pharmaceuticals Inc |
2.46%
250,000
|
$60,750,000,000 | 1.84% |
| Mirum Pharmaceuticals Inc |
4.55%
1,772,038
|
$60,585,979,000 | 1.83% |
| Merus N.V |
12.69%
1,001,073
|
$59,233,489,000 | 1.79% |
| Idexx Labs Inc |
33.33%
119,500
|
$58,220,400,000 | 1.76% |
| agilon health, inc. |
0.74%
8,900,000
|
$58,206,000,000 | 1.76% |
| Dexcom Inc |
16.21%
500,000
|
$56,690,000,000 | 1.72% |
| Humana Inc. |
No change
147,408
|
$55,078,999,000 | 1.67% |
| Insmed Inc |
Opened
808,356
|
$54,159,852,000 | 1.64% |
| Rhythm Pharmaceuticals Inc. |
15.92%
1,280,493
|
$52,577,043,000 | 1.59% |
| Celldex Therapeutics Inc. |
1.95%
1,398,994
|
$51,776,768,000 | 1.57% |
| Phreesia Inc |
2.22%
2,417,500
|
$51,251,000,000 | 1.55% |
| Edwards Lifesciences Corp |
15.03%
550,000
|
$50,803,500,000 | 1.54% |
| Xenon Pharmaceuticals Inc |
1.38%
1,272,877
|
$49,629,474,000 | 1.50% |
| West Pharmaceutical Svsc Inc |
6.01%
145,500
|
$47,926,245,000 | 1.45% |
| Penumbra Inc |
47.52%
265,000
|
$47,692,050,000 | 1.44% |
| Exact Sciences Corp. |
2.05%
1,081,500
|
$45,693,375,000 | 1.38% |
| Agios Pharmaceuticals Inc |
40.82%
1,044,261
|
$45,028,534,000 | 1.36% |
| Sarepta Therapeutics Inc |
13.31%
284,000
|
$44,872,000,000 | 1.36% |
| Shockwave Med Inc |
Closed
135,000
|
$43,960,050,000 | |
| iRhythm Technologies Inc |
1.34%
397,500
|
$42,786,900,000 | 1.29% |
| Ascendis Pharma A/S |
No change
290,000
|
$39,550,200,000 | 1.20% |
| Insulet Corporation |
39.06%
195,000
|
$39,351,000,000 | 1.19% |
| Structure Therapeutics Inc |
142.30%
999,862
|
$39,264,581,000 | 1.19% |
| Travere Therapeutics Inc |
30.88%
4,482,265
|
$36,844,218,000 | 1.11% |
| Azenta Inc |
0.18%
696,000
|
$36,623,520,000 | 1.11% |
| Revolution Medicines Inc |
2.11%
943,195
|
$36,605,398,000 | 1.11% |
| Kymera Therapeutics, Inc. |
23.54%
1,163,973
|
$34,744,594,000 | 1.05% |
| Mereo BioPharma Group plc |
14.02%
9,283,492
|
$33,420,571,000 | 1.01% |
| Warby Parker Inc. |
No change
2,080,000
|
$33,404,800,000 | 1.01% |
| Immunovant Inc |
3.09%
1,185,654
|
$31,301,266,000 | 0.95% |
| Align Technology, Inc. |
42.05%
127,500
|
$30,782,325,000 | 0.93% |
| Surgery Partners Inc |
Closed
985,000
|
$29,382,550,000 | |
| Akero Therapeutics Inc |
17.36%
1,074,261
|
$25,202,163,000 | 0.76% |
| Johnson & Johnson |
Opened
170,000
|
$24,847,200,000 | 0.75% |
| Lifestance Health Group Inc |
1.00%
4,827,700
|
$23,704,007,000 | 0.72% |
| Cerevel Therapeutics Hldng I |
Closed
547,946
|
$23,161,677,000 | |
| Disc Medicine Inc |
Closed
363,468
|
$22,629,518,000 | |
| Zai Lab Ltd |
0.06%
1,297,873
|
$22,492,139,000 | 0.68% |
| Pacira BioSciences Inc |
25.63%
785,000
|
$22,458,850,000 | 0.68% |
| Legend Biotech Corp |
1.26%
505,786
|
$22,401,262,000 | 0.68% |
| Biocryst Pharmaceuticals Inc. |
3.52%
3,619,258
|
$22,367,014,000 | 0.68% |
| Collegium Pharmaceutical Inc |
Closed
562,000
|
$21,816,840,000 | |
| Viking Therapeutics Inc |
Closed
261,000
|
$21,402,000,000 | |
| Novo-nordisk A S |
No change
147,500
|
$21,054,150,000 | 0.64% |
| Oscar Health, Inc. |
40.69%
1,251,500
|
$19,798,730,000 | 0.60% |
| Nuvalent Inc |
104.30%
255,989
|
$19,419,326,000 | 0.59% |
| Krystal Biotech Inc |
1.54%
105,569
|
$19,386,691,000 | 0.59% |
| Inspire Med Sys Inc |
0.38%
130,000
|
$17,397,900,000 | 0.53% |
| Inozyme Pharma, Inc. |
0.47%
3,698,374
|
$16,494,748,000 | 0.50% |
| Dyne Therapeutics, Inc. |
2.04%
461,028
|
$16,269,678,000 | 0.49% |
| Dynavax Technologies Corp. |
22.85%
1,292,637
|
$14,516,314,000 | 0.44% |
| Pharvaris N V |
0.53%
756,931
|
$14,230,303,000 | 0.43% |
| Immunocore Hldgs Plc |
82.30%
419,030
|
$14,200,927,000 | 0.43% |
| Vera Therapeutics Inc |
11.73%
381,192
|
$13,791,527,000 | 0.42% |
| Crinetics Pharmaceuticals In |
No change
289,400
|
$12,962,226,000 | 0.39% |
| Prothena Corp Plc |
No change
625,048
|
$12,900,991,000 | 0.39% |
| Olink Hldg Ab |
70.18%
500,000
|
$12,740,000,000 | 0.39% |
| Charles Riv Labs Intl Inc |
24.23%
60,250
|
$12,446,445,000 | 0.38% |
| Biomarin Pharmaceutical Inc. |
1.46%
151,000
|
$12,431,830,000 | 0.38% |
| Amicus Therapeutics Inc |
5.72%
1,218,580
|
$12,088,314,000 | 0.37% |
| Nevro Corp |
29.72%
1,381,500
|
$11,632,230,000 | 0.35% |
| Cullinan Therapeutics Inc |
Opened
658,338
|
$11,481,415,000 | 0.35% |
| Enliven Therapeutics Inc |
No change
428,571
|
$10,015,704,000 | 0.30% |
| Jasper Therapeutics Inc |
No change
404,335
|
$9,178,405,000 | 0.28% |
| Immatics N.v |
Closed
848,751
|
$8,920,373,000 | |
| Novavax, Inc. |
25.55%
675,000
|
$8,545,500,000 | 0.26% |
| Accolade, Inc. |
35.31%
2,290,000
|
$8,198,200,000 | 0.25% |
| EDAP TMS S.A. |
No change
1,475,000
|
$8,024,000,000 | 0.24% |
| SpringWorks Therapeutics, Inc. |
Opened
199,855
|
$7,528,538,000 | 0.23% |
| Cg Oncology Inc |
Closed
170,859
|
$7,500,710,000 | |
| Neumora Therapeutics Inc. |
17.63%
760,007
|
$7,470,869,000 | 0.23% |
| Applied Therapeutics, Inc. |
3.81%
1,555,004
|
$7,261,869,000 | 0.22% |
| Aurinia Pharmaceuticals Inc |
2.56%
1,179,740
|
$6,736,315,000 | 0.20% |
| Mersana Therapeutics Inc |
No change
3,046,782
|
$6,124,032,000 | 0.19% |
| Beam Therapeutics Inc. |
69.43%
249,923
|
$5,855,696,000 | 0.18% |
| Acumen Pharmaceuticals Inc |
No change
2,300,059
|
$5,566,143,000 | 0.17% |
| Compass Therapeutics Inc |
No change
5,513,788
|
$5,513,788,000 | 0.17% |
| Apellis Pharmaceuticals Inc |
Opened
140,700
|
$5,397,252,000 | 0.16% |
| Fulcrum Therapeutics Inc |
No change
727,673
|
$4,511,573,000 | 0.14% |
| Macrogenics Inc |
19.28%
1,053,647
|
$4,478,000,000 | 0.14% |
| Mineralys Therapeutics Inc |
52.19%
378,932
|
$4,433,504,000 | 0.13% |
| Biohaven Ltd |
0.45%
127,558
|
$4,427,538,000 | 0.13% |
| Pliant Therapeutics, Inc. |
No change
384,996
|
$4,138,707,000 | 0.13% |
| Pulmonx Corp |
No change
652,400
|
$4,136,216,000 | 0.13% |
| Perspective Therapeutics Inc |
Opened
401,196
|
$3,999,924,000 | 0.12% |
| Autolus Therapeutics plc |
No change
1,032,988
|
$3,594,798,000 | 0.11% |
| Essa Pharma Inc |
No change
677,005
|
$3,561,046,000 | 0.11% |
| Aclaris Therapeutics Inc |
No change
2,753,495
|
$3,028,845,000 | 0.09% |
| Gossamer Bio, Inc. |
No change
3,266,960
|
$2,943,204,000 | 0.09% |
| Amylyx Pharmaceuticals Inc |
Closed
1,011,412
|
$2,872,410,000 | |
| Xilio Therapeutics Inc |
108.45%
3,003,259
|
$2,845,588,000 | 0.09% |
| Sagimet Biosciences Inc |
2.22%
787,808
|
$2,694,303,000 | 0.08% |
| Leap Therapeutics Inc |
38.89%
1,266,546
|
$2,482,430,000 | 0.08% |
| Adaptimmune Therapeutics Plc |
No change
2,425,468
|
$2,364,589,000 | 0.07% |
| Vigil Neuroscience Inc |
No change
471,958
|
$1,887,832,000 | 0.06% |
| Compugen Ltd |
23.26%
989,990
|
$1,663,183,000 | 0.05% |
| Spruce Biosciences, Inc. |
No change
2,609,125
|
$1,350,744,000 | 0.04% |
| Kyverna Therapeutics Inc |
No change
178,963
|
$1,342,223,000 | 0.04% |
| Reneo Pharmaceuticals Inc |
Closed
751,730
|
$1,247,872,000 | |
| Korro Bio Inc |
Opened
35,719
|
$1,209,803,000 | 0.04% |
| Allakos Inc |
Opened
1,200,409
|
$1,200,409,000 | 0.04% |
| Biomea Fusion Inc |
No change
181,147
|
$815,162,000 | 0.02% |
| Vincerx Pharma Inc |
No change
891,719
|
$722,292,000 | 0.02% |
| Talphera Inc |
No change
316,460
|
$281,649,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 116 holdings | |||
Hedge funds similar to Rock Springs Capital Management L.P.
- Members Trust Co
- Marsico Capital Management
- Bls Capital Fondsmaeglerselskab A/s
- Norinchukin Bank, The
- Grimes & Company, Inc
- Continental Casualty
- Wit
- Acr Alpine Capital Research
- Massmutual Trust Co Fsb/adv
- Aristotle Capital Boston
- Fort Pitt Capital Group
- Empirical Services, D.b.a. Empirical Wealth Management
- First Horizon Advisors
- Exor N.v